Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.74 |
| ▸ | CA9 | Q16790 | 2/20 | 0.74 |
| ▸ | CA1 | P00915 | 1/20 | 0.74 |
| ▸ | CA2 | P00918 | 1/20 | 0.74 |
| ▸ | CA7 | P43166 | 1/20 | 0.74 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.74 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.58 |
| ▸ | NDUFS8 | O00217 | 2/20 | 0.58 |
| ▸ | COXFA4 | O00483 | 2/20 | 0.58 |
| ▸ | NDUFAB1 | O14561 | 2/20 | 0.58 |
| ▸ | NDUFA1 | O15239 | 2/20 | 0.58 |
| ▸ | NDUFS4 | O43181 | 2/20 | 0.58 |
| ▸ | NDUFB5 | O43674 | 2/20 | 0.58 |
| ▸ | NDUFB3 | O43676 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ostruthin SCHEMBL2936116 | 1.00 | CA12 (0.74) | CA12CA9CA1CA2CA7 | |
| Demethylsuberosin SCHEMBL4773171 | 0.89 | CA9 (0.78) | CA12CA9CA1CA2CA7 | |
| SCHEMBL4882410 | 0.79 | CA9 (0.71) | CA12CA9CA1CA2CA7 | |
| SCHEMBL4882406 | 0.79 | CA9 (0.71) | CA12CA9CA1CA2CA7 | |
| SCHEMBL9714250 | 0.77 | PTPN1 (0.61) | PPARGBACE1PTPN1ALOX5PTGS1 | |
| SCHEMBL9714237 | 0.77 | PTPN1 (0.61) | PPARGBACE1PTPN1ALOX5PTGS1 | |
| SCHEMBL24075636 | 0.76 | MAOA (0.78) | SRD5A1ALOX15KDM4EALDH1A1CYP3A4 | |
| SCHEMBL4540197 | 0.76 | VKORC1 (0.60) | CA12CA9ALOX15KDM4EALDH1A1 | |
| SCHEMBL30158338 | 0.76 | MAOA (0.78) | SRD5A1ALOX15KDM4EALDH1A1CYP3A4 | |
| SCHEMBL4540200 | 0.76 | VKORC1 (0.60) | CA12CA9ALOX15KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2022182523-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2021158575-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021158573-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| US-20260048025-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | NATURAL EXTRACTION SYS LLC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20250311723-A1 | METHODS AND COMPOSITIONS FOR ALTERING SECONDARY METABOLITES IN PLANTS | IMPELLO BIOSCIENCES, INC. | 2025-10-09 | — | — | US | disclosed |
| US-12409152-B2 | Compositions and methods related to dissolved oxides | Natural Extraction Systems, LLC (US) | 2025-09-09 | — | — | US | disclosed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | disclosed |
| US-12065679-B2 | Aspergillus oryzae and its application | WENZHOU UNIVERSITY (CN) | 2024-08-20 | — | — | US | disclosed |
| US-20240150269-A1 | PROCESSES FOR THE PREPARATION OF ORTHO-ALLYLATED HYDROXY ARYL COMPOUNDS | MCMASTER UNIVERSITY (CA) | 2024-05-09 | — | — | US | disclosed |
| US-20240041062-A1 | FILLERS FOR CHOCOLATE AND OTHER CONSUMABLES | Voyage Foods, Inc. | 2024-02-08 | — | — | US | disclosed |
| EP-2229169-A1 | PREPARATION CONTAINING CHROMANE-2-ONE DERIVATIVES | Merck Patent GmbH (DE) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009089880-A1 | PREPARATION CONTAINING CHROMANE-2-ONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-07-23 | — | — | WO | disclosed |
| WO-2008100977-A2 | CARBAMATES THERAPEUTIC RELEASE AGENTS AS AMIDASE INHIBITORS | N.V. ORGANON (NL) | 2008-08-21 | — | — | WO | disclosed |
| WO-2007115181-A9 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEM CO (US) | 2008-04-03 | — | — | WO | disclosed |
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | EASTMAN CHEMICAL COMPANY | 2007-11-01 | — | — | US | disclosed |
| WO-2007115181-A2 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEMICAL COMPANY (US) | 2007-10-11 | — | — | WO | disclosed |
| WO-2006094327-A1 | PHARMACEUTICAL PREPARATION FOR TREATING MYCOBACTERIAL INFECTIONS | Universität Graz (AT) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | ABCC4, NCOA4, NR4A3 | CA12 4180/4885CA9 2021/4885CA1 3736/4885 |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | CA12 819/4885CA9 655/4885CA1 666/4885 |
| US-20250311723-A1 | METHODS AND COMPOSITIONS FOR ALTERING SECONDARY METABOLITES IN PLANTS | ERG28, AHCY, BROX | CA12 2899/4885CA9 2263/4885CA1 3522/4885 |
| US-12409152-B2 | Compositions and methods related to dissolved oxides | PRKG2, PRKG1, CIT | CA12 262/4885CA9 159/4885CA1 61/4885 |
| US-20240150269-A1 | PROCESSES FOR THE PREPARATION OF ORTHO-ALLYLATED HYDROXY ARYL COMPOUNDS | ADH1A, ADH1C, AHR | CA12 3047/4885CA9 1745/4885CA1 1621/4885 |
| US-20260048025-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | SCO2, CNR2, CNR1 | CA12 315/4885CA9 1360/4885CA1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.